Predictors of antibody persistence to the 7-valent pneumococcal conjugate vaccine in healthy Fijian infants at 12 months of age

Little is known about the predictors of antibody persistence to pneumococcal conjugate vaccines (PCV) in the context of reduced dose schedules. In Fiji, an RCT investigated 0, 1, 2 and 3 dose schedules of 7-valent PCV administered at 6, 10 and 14 weeks of age in 364 healthy infants. This study was a...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccine Vol. 38; no. 33; pp. 5095 - 5099
Main Authors:	Lindholm, Daniel E., Licciardi, Paul V., Ratu, Felisita T., Kim Mulholland, E., Nguyen, Cattram D., Russell, Fiona M.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 14.07.2020 Elsevier Limited
Subjects:	Age Allergy and Immunology Antibiotics Antibodies Antibodies, Bacterial Antigens Breastfeeding & lactation Conjugates Cultural differences Ethnicity Families & family life Family income Fiji Health risk assessment Households Humans IgG antibody Immunoglobulin G Infant Infants nationalities and ethnic groups odds ratio Opsonophagocytosis Pneumococcal conjugate vaccine Pneumococcal Infections - prevention & control Pneumococcal Vaccines Poor antibody persistence Reduced-dose schedule risk Schedules Streptococcus infections Streptococcus pneumoniae Tetanus Vaccines Vaccines, Conjugate Fiji Pneumococcal conjugate vaccine PCV RCT Fiji aOR CI Poor antibody persistence IgG Infant Reduced-dose schedule HPV PCV7 Ethnicity URTI OI immunoglobulin G 7-valent pneumococcal conjugate vaccine opsonophagocytic index randomised control trial adjusted odds ratio confidence interval human papillomavirus vaccine upper respiratory tract infection
ISSN:	0264-410X, 1873-2518, 1873-2518
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!